Operations strategy for a scalable CGT supply chain: key CXO insights

Shesh Sharma, Tim Sirichoke, Edward Ballesteros

02 December 2024

Expert Insight

The sweet cell of success: key considerations for the sourcing and production of pluripotent cell lines for therapeutic development

Samuel JI Blackford, Nathan C Manley

21 May 2024

Expert Insight

Raw materials and supplies for cell therapies: end to end expectations and best practices

Lili Belcastro

15 May 2024

Expert Insight

Innovation in hematopoietic stem cell cryopreservation and cold chain management

M Prisciandaro, M Santodirocco, G Fania et al

30 April 2024

Expert Insight

A straightforward tool for developing a raw material supply strategy for cell & gene therapies

K Kulenkampff, R Eigenmann, D Karlstetter et al

08 January 2024

Expert Insight

Considerations for development of gene-edited PSC-based therapies

Brent Morse, Amanda Mack

14 November 2023

Expert Insight

The supporting role of plasmids in gene & cell therapy

Duarte Prazeres

06 July 2023

Expert Insight

Challenges in obtaining cellular therapy starting material for patients with sickle cell disease

Yvette C Tanhehco

22 March 2023

Expert Insight

Taking lessons from nature to improve cell therapy cryopreservation

Jason Acker, Nishaka William, Mackenzie Coatham

20 March 2023

Expert Insight

Implementing demand & operations planning in clinical cell & gene therapy

Peter Horton

26 January 2023

Expert Insight

Considerations for use of hematopoietic stem cells in allogeneic therapies

Barbara Seymour

08 March 2022

Expert Insight

Banking on the future of regenerative medicine with cGMP-compliant iPSC lines

Melissa K Carpenter

22 February 2022

Expert Insight

Umbilical cord blood NK cells offer multiple advantages for cancer immunotherapy: lessons learned from Glycostem’s orphan drug oNKord®

Volker Huppert

14 January 2022

Expert Insight

Navigating regulations to provide ethically sourced cellular material for research and development: UK perspective

Salmah Ahmed

11 January 2022

Expert Insight

The case for the use of pooled donors in the manufacture of allogeneic cell therapies

Benjamin Weil, Mark Lowdell

24 March 2021

Expert Insight

Limiting variability to achieve reproducibility in cell manufacturing

Anne Lamontagne, Andrew Fesnak

11 November 2020

Expert Insight

The supply chain: key considerations for biological starting material for ATMPs production

Elisabet Aguilar

22 September 2020

Expert Insight

Using serum-free media to streamline and optimize CAR T-cell manufacturing workflows

Chengkang (CK) Zhang, Amber Jones

10 September 2020

Expert Insight

Utilization of risk-based approach to characterize starting material for autologous CAR-T manufacturing

Jean Stanton

08 September 2020

Expert Insight

Supply chain challenges and issues facing the autologous cell manufacturing industry

K Wang, B Wang, C White et al

24 April 2020

Expert Insight

Developing and implementing a supply chain management system for cellular therapy programs

David L DiGiusto, Rakib Ouro-Djobo, Uzair Rajput

09 April 2020

Expert Insight